Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gil I Wolfe

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
JAMA Neurology|March 24, 2020
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical TrialsMerit Cudkowicz, Marianne K Chase, Christopher S Coffey, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
JAMA Neurology|March 24, 2020
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical TrialsMerit Cudkowicz, Marianne K Chase, Christopher S Coffey, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 11